Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

3 Companies That Might Acquire Rite Aid

Page 1 of 2

Is it possible that Rite Aid Corporation (NYSE:RAD) will be acquired by one of its larger competitors – Walgreen or CVS? The answer is likely “no.” However, does this mean that Rite Aid’s chances of being acquired are slim-to-none, and why is it that Rite Aid is such a compelling acquisition target in the first place?

The unlikely super pharmacy
In a previous article, “Will This Pharmacy Company be Acquired, and Is It Needed?” I explained why companies like Walgreen and CVS would not acquire Rite Aid.

Rite Aid Corporation (NYSE:RAD)

The fact that Rite Aid would make either CVS or Walgreen super-pharmacies might sound appealing, but much like the FCC denied AT&T’s acquisition attempt of T-Mobile – due to it creating an unfair advantage and hurting the free market – the government is unlikely to allow such a merger.

However, in the noted article, I explained that because Rite Aid is just one-fifth as expensive as either Walgreen or CVS on a price/sales comparison, and is seeing the greatest margin improvement, that an acquisition is not needed for Rite Aid to trade significantly higher.

While this statement may be true, Walgreen and CVS might not be the only companies to see value in Rite Aid. In fact, due to the company’s size, and its return to profitability, there are several companies that might see Rite Aid’s benefit too great to pass up.

The mini-store mania
Back in 2011, retail juggernaut Wal-Mart Stores, Inc. (NYSE:WMT) announced a mini-store concept, which it called “Express” stores . In these stores, Wal-Mart will focus on its most profitable and best-selling products, which include drugs.

Wal-Mart’s Express stores will be just one-tenth the size of its Supercenters, or less than 15,000 square feet. Ironically, Rite Aid stores are about this size, and by acquiring Rite Aid, Wal-Mart would gain more than 4,000 stores!

Currently, Wal-Mart has over 4,500 stores that sell Rx, including Sam’s Club, and reported over $17 billion in Rx sales during 2012. While impressive, $17 billion is less than half of the Rx sales produced by Walgreen or CVS. By acquiring Rite Aid, Wal-Mart could satisfy its mini-store goals plus be equal to numbers one and two in the pharmacy space.

Not to mention, with new generic introductions creating higher margins among pharmacies – as generic drugs pay more per script to pharmacies than brand name drugs – and countless blockbuster drugs losing patents in the coming three years, now looks better than ever for Wal-Mart to make such an acquisition.

With $116 billion in gross profit over the last year, Wal-Mart could easily afford Rite Aid.

An under-the-radar player in the game
Target Corporation (NYSE:TGT)
 is not what most consider significant in the retail pharmacy space. In 2012, Target ranked 10 in U.S. Rx sales, reporting just $3.3 billion of its $73 billion from pharmacy. However, the 4.5% of total sales that Target earned from Rx outweighs the 3.6% that Wal-Mart earned with its $17 billion in Rx sales ($469 billion total sales).

So, why would Target be interested in Rite Aid? Well, for the same reasons as Wal-Mart: The pharmacy industry is producing higher margins with new generic introductions; there are many new generics to be introduced in coming years; Rite Aid would drastically increase Target’s total number of stores with Rx (1,647 in 2012 ) and give Target a mini-store presence.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!